Presence of HBsAg and anti-HBs in patients with primary liver cancer or hepatic metastases.
The presence of HBsAg was detected in the serum of 1 out of 13 patients with chronic hepatitis, in 2 out of the 7 patients with liver metastases, but in none of the 10 patients with hepatocellular carcinoma (HCC) investigated. HBsAg could be visualized by orcein staining in the liver cells of 66.6% of the HCC patients, in 50% of the patients with liver metastases and in 40% of the patients with liver cirrhosis. The prevalence of anti-HBs was low both in HCC patients and in the control groups. The possible significance of these findings is discussed.
D002759:Adenoma, Bile Duct / Q000276:immunology; D001650:Bile Duct Neoplasms / Q000276:immunology; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000276:immunology* / Q000556:secondary; D004444:Echinococcosis, Hepatic / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006521:Hepatitis, Chronic / Q000276:immunology; D006801:Humans; D005779:Immunodiffusion; D007244:Infectious Mononucleosis / Q000276:immunology; D008099:Liver / Q000276:immunology; D008103:Liver Cirrhosis / Q000276:immunology; D008113:Liver Neoplasms / Q000209:etiology / Q000276:immunology* / Q000556:secondary; D012509:Sarcoma / Q000276:immunology; D013274:Stomach Neoplasms / Q000276:immunology
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens